Zevra Therapeutics (FRA:1GDA) FCF Margin % : -471.98% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zevra Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €-14.87 Mil. Zevra Therapeutics's Revenue for the three months ended in Mar. 2024 was €3.15 Mil. Therefore, Zevra Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -471.98%.

As of today, Zevra Therapeutics's current FCF Yield % is -23.72%.

The historical rank and industry rank for Zevra Therapeutics's FCF Margin % or its related term are showing as below:

FRA:1GDA' s FCF Margin % Range Over the Past 10 Years
Min: -185.12 Med: -123.2 Max: 36.08
Current: -163.97

During the past 11 years, the highest FCF Margin % of Zevra Therapeutics was 36.08%. The lowest was -185.12%. And the median was -123.20%.

FRA:1GDA's FCF Margin % is ranked worse than
51.87% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs FRA:1GDA: -163.97

Zevra Therapeutics FCF Margin % Historical Data

The historical data trend for Zevra Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics FCF Margin % Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-185.08

-14.84

36.08

-185.12

-123.20

Zevra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-128.29	-103.03	-165.76	-122.80	-471.98

Competitive Comparison of Zevra Therapeutics's FCF Margin %

For the Biotechnology subindustry, Zevra Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's FCF Margin % falls into.

Zevra Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Zevra Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-31.023	/	25.182
	=	-123.20 %

Zevra Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-14.872	/	3.151
	=	-471.98 %

Zevra Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ZVRA:USA 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines